2022
Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research
Kunst N, Stout N, O’Brien G, Christensen K, McMahon P, Wu A, Diller L, Yeh J. Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research. Journal Of The National Cancer Institute 2022, 114: 722-731. PMID: 35043946, PMCID: PMC9086756, DOI: 10.1093/jnci/djac013.Peer-Reviewed Original ResearchConceptsUsual careClinical benefitTP53 variantsIncremental cost-effectiveness ratioPathogenic TP53 variantsCancer-related deathGermline TP53 variantsUS birth cohortPotential health outcomesCost-effectiveness ratioIdentification of childrenTumor surveillanceClinical studiesRhabdomyosarcoma casesPediatric cancerEarly cancer detectionRoutine surveillanceBirth cohortHealth outcomesAge 20Newborn screeningMalignancy detectionFurther researchCareTP53
2020
Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States
Kunst N, Alarid-Escudero F, Aas E, Coupé VMH, Schrag D, Kuntz KM. Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 2710-2718. PMID: 32998946, PMCID: PMC7747688, DOI: 10.1158/1055-9965.epi-20-0490.Peer-Reviewed Original ResearchConceptsCancer recurrence rateRecurrence rateRelative survival dataColorectal cancerSurvival dataColorectal cancer-related deathsDisease-specific survival dataStage II rectal cancerStage III colorectal cancerCancer-specific death ratesStage II colon cancerPopulation-based cancer registriesColorectal cancer interventionDiagnostic time periodsMetastatic recurrence ratesRate 6 monthsNonmetastatic colorectal cancerColorectal cancer recurrenceMonths of diagnosisAnnual recurrence rateEnd Results ProgramCancer-related deathColorectal cancer diagnosisDecision analytic modelMetastatic disease